Login to Your Account

Biomarin serves up ‘bloody good data’ on BMN 270

By Marie Powers
News Editor

Thursday, July 28, 2016

Interim results from the open-label phase I/II study of BMN 270, Biomarin Pharmaceutical Inc.’s gene therapy to treat severe hemophilia A, showed the candidate outperformed expectations.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription